4results about How to "Low hemolytic toxicity" patented technology

The invention provides a short-chain antibacterial peptide with anti-Candida albicans activity and application of the short-chain antibacterial peptide. The antibacterial peptide is a derivative peptide Pm-2W modified from an antibacterial peptide obtained from Hainan ubiquitous frog. Belongs to the field of application of peptide antibiotics. Antibacterial peptide is modified to obtain the derivative peptide Pm-2W; the Pm-2W disclosed by the invention has efficient activity of resisting candida albicans; the Pm-2W has anti-Candida albicans biofilm activity, is not easy to induce drug resistance, has high stability and low hemolytic toxicity, can be applied to preparation of drugs or bacteriostatic agents for treating Candida albicans infection and the like, and has a good application prospect.

The invention discloses a group of low-toxicity broad-spectrum antibacterial peptides containing a central PXXP hinge structure and application of the low-toxicity broad-spectrum antibacterial peptides. The low-toxicity broad-spectrum antibacterial peptide is obtained by adopting a de novo design mode, using lysine (Lys, K) with positive charges and hydrophobic tryptophan (Trp, W), alternately, repeatedly and symmetrically arranging two amino acids, and introducing a PXXP hinge structure containing proline into the symmetric center of an antibacterial peptide sequence. The structural general formula is (KW) nPXXP (WK) n, XX = KK, n = 2-4, or XX = WK, n = 2-3. An in-vitro antibacterial experiment shows that the antibacterial peptide disclosed by the invention has broad-spectrum antibacterial activity; the preferred antibacterial peptide has the advantages of low hemolysis toxicity and high serum stability. Induced drug resistance experiments show that the preferred antibacterial peptide has the characteristic of low drug resistance generation. An in-vivo acute toxicity experiment result shows that compared with a contrast drug Polymyxin B, the preferable antibacterial peptide disclosed by the invention has higher in-vivo safety. Therefore, the compound has a good application prospect in preparation of clinical antibacterial drugs, and is expected to become a novel antibiotic candidate drug.

This invention discloses an antimicrobial 10-peptide, characterized by the sequence: w-k-r-w-r-r-w-w-r-r(dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), where all amino acids are D-type amino acids. The antimicrobial peptide provided by this invention exhibits good antimicrobial activity against a variety of pathogenic bacteria. This antimicrobial peptide can be synthesized using the Fmoc solid-phase chemical method, which is easy to synthesize and exhibits good in vivo antimicrobial activity. This antimicrobial peptide exhibits broad-spectrum killing activity against multidrug-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, as well as standard strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus. It has low hemolytic toxicity, and at low to medium concentrations (2 μg / mL to 32 μg / mL), the cell survival rate can reach more than 50%. It has no toxic effect on cells, good stability, strong operability, and low cost.

The invention belongs to the technical field of biology, and particularly relates to a scrota-derived antibacterial peptide and application thereof. The antibacterial peptide from the scrota is SPC-1 or SPC-2, and the antibacterial peptide from the scrota is SPC-2; wherein the amino acid sequence of the SPC-1 is as shown in a sequence table SEQ ID NO. 1, and the amino acid sequence of the SPC-2 is as shown in a sequence table SEQ ID NO. 2. The scrota antibacterial peptide provided by the invention is novel in amino acid sequence, has remarkable antibacterial activity on gram-negative bacteria and gram-positive bacteria, shows broad-spectrum antibacterial property, and has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and by virtue of the characteristics, the scrota antibacterial peptide shows excellent antibacterial value; and a new resource is provided for the development of antibacterial products against the human pathogenic bacteria.